| 2024/10/18 21:36:29 | |
|---|---|
| Price | |
| 61.756 USD | |
| Difference | 1.74% (1.06) |
General attributes
| ISIN | FR0014000MR3 |
| Symbol | ERF |
| Exchange | FINRA other OTC Issues |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 10,797 EUR |
| Benchmark | ATX AUSTRIAN TRADED INDEX |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 59.25 USD |
| High | 61.764 USD |
| Low | 58.84 USD |
| Close (prev. day) | 60.6978 USD |
| VWAP | 60.745631 USD |
| Volume (pcs) | 344 |
| Trading volume | 20,896.50 |
| Number of trades | 9 |
| Last size | 6 |
Futures and Options
| Related Futures | 21 |
| Related Options | - |
PDF Downloads
| Company report: EUROFINS SCIENTIFIC S.E. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/09/27 |
|
Global Equity Ratings |
|
| 2024/09/11 |
|
Global Equity Ratings |
|
| 2024/09/05 |
|
Global Equity Ratings |
|
| 2024/08/12 |
|
Global Equity Ratings |
|
| 2024/07/24 |
|
Global Equity Ratings |
|
| 2024/10/18 21:36:29 | |
|---|---|
| Price | |
| 61.756 USD | |
| Difference | 1.74% (1.06) |
General attributes
| ISIN | FR0014000MR3 |
| Symbol | ERF |
| Exchange | FINRA other OTC Issues |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 10,797 EUR |
| Benchmark | ATX AUSTRIAN TRADED INDEX |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 59.25 USD |
| High | 61.764 USD |
| Low | 58.84 USD |
| Close (prev. day) | 60.6978 USD |
| VWAP | 60.745631 USD |
| Volume (pcs) | 344 |
| Trading volume | 20,896.50 |
| Number of trades | 9 |
| Last size | 6 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -2.03% | +22.00% | -51.17% |
| Perf (abs.) | -1.28 | +11.14 | -64.72 |
| Beta | 0.32 | 0.60 | 0.40 |
| Volatility | 67.49 | 56.43 | 50.96 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 60.768 USD (804) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 59.728 USD (911) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 57.171 USD (1,915) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 59.156 USD (1,901) |
| YTD High | date | 68.450 USD (2024/04/23) |
| YTD Low | date | 44.610 USD (2024/06/24) |
| 52 Weeks High | date | 68.450 USD (2024/04/23) |
| 52 Weeks Low | date | 44.610 USD (2024/06/24) |
All listings for EUROFINS SCIENTIFIC S.E.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/10/18 | 17:35 | 55.46 EUR | 0.00 | 2 |
| Vienna Stock Exchange | 2024/10/18 | 15:30 | 56.20 EUR | 0.00 | 4 |
| Tradegate | 2024/10/18 | 22:26 | 56.44 EUR | 0.04 | 8 |
| Stuttgart | 2024/10/18 | 15:47 | 55.98 EUR | 0.00 | 10 |
| Munich | 2024/10/18 | 08:05 | 55.96 EUR | 0.00 | 2 |
| London Stock Exchange European Trade Reporting | 2024/10/18 | 17:30 | 56.20 EUR | 0.00 | 2 |
| Hanover | 2024/10/18 | 17:25 | 55.94 EUR | 0.00 | 4 |
| Hamburg | 2024/10/18 | 17:25 | 55.94 EUR | 0.00 | 4 |
| Frankfurt | 2024/10/18 | 15:29 | 55.58 EUR | 0.00 | 1 |
| FINRA other OTC Issues | 2024/10/18 | 21:36 | 61.756 USD | 0.02 | 9 |
| Euronext Paris | 2024/10/18 | 17:35 | 56.42 EUR | 14.71 | 2,250 |
| Euronext Milan MTF Trading After Hours | - | - | - | 0.00 | - |
| Duesseldorf | 2024/10/18 | 08:11 | 55.94 EUR | 0.00 | 3 |
| Berlin | 2024/10/18 | 08:08 | 56.00 EUR | 0.00 | 2 |
Company Logo
Contact Details
| EUROFINS SCIENTIFIC SE |
| - - |
| 23 Val Fleuri - 1526 Luxembourg |
| Telefon: +352-26-18-53-20 |
| Fax: +352-26-18-53-31 |
| E-mail: info@eurofins.com |
PDF Downloads
| Company report: EUROFINS SCIENTIFIC S.E. | |
Company Profile
Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg. |
Members of Management Board
| Gilles Martin | Chairman of Managing Board |
| Christian Wurst | Member of Executive Committee |
| Christopher Hervé | Member of Executive Committee |
| François Vigneau | Member of Executive Committee |
| Laurent Lebras | Member of Executive Committee |
Board of directors
| Yves-Loïc Martin | Member of Supervisory Board |
| Erica Monfardini | Member of Supervisory Board |
| Evie Roos | Member of Supervisory Board |
| Ivo Rauh | Member of Supervisory Board |
| Pascal Rakovsky | Member of Supervisory Board |
| Patrizia Luchetta | Member of Supervisory Board |
| Valérie Hanote | Member of Supervisory Board |